World Hemophilia Day 2021, Kedrion alongside patients
Today, more than ever, the company is close to those who are in a vulnerable condition
Rh&Life, first subject included in the study
Two hundred pregnant women to be enrolled over five countries
KIDCARES10, first patient enrolled in pediatric PI study
Thirty patients aged 2 to 17 years old to be enrolled over five European countries
Updates on anti-COVID treatment developed by Kamada and Kedrion
Top-line results announced from the phase 1/2 clinical trial in Israel
CARES10 clinical trial: last patient treated in the USA
Study to assess efficacy, safety and pharmacokinetics of a 10 percent Immunoglobulin in PI patients
Turkey, Kedrion supports the XVII International Congress on Hemophilia
The present and future role of Factor VIII at the center of the symposium supported by Kedrion
Kedrion is one of the main sponsors of the National SISET Conference
The company sponsors two scientific lectures, a testament to its close ties with the world of medicine and science
Global Plasma Summit, Kedrion among the protagonists of the PPTA initiative
Paolo Marcucci, President of the company, received the prestigious “Otto Schwartz” Award
Covid-19, Kedrion supports a webinar on the management of Coagulopathy
The purpose of the event is to improve understanding of one of the major complications associated with the virus